Janux Therapeutics (JANX) EBITDA (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of EBITDA data on file, last reported at -$28.1 million in Q1 2026.

• Quarterly EBITDA fell 28.23% year-over-year to -$28.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$117.7 million (down 60.16% YoY) and the FY2025 annual result came in at -$111.5 million, down 65.15% from the prior year.
• EBITDA advanced to -$28.1 million in Q1 2026 per JANX's latest filing, from -$32.2 million in the prior quarter.
• Across five years, EBITDA topped out at -$7.1 million in Q2 2024 and bottomed at -$33.9 million in Q2 2025.
• The 5-year median for EBITDA is -$17.2 million (2022), against an average of -$19.3 million.
• The widest annual swing landed in 2022, when EBITDA tumbled 555.74%; it then soared 60.45% in 2024.
• Tracing JANX's EBITDA over 5 years: stood at -$15.3 million in 2022, then soared by 35.27% to -$9.9 million in 2023, then plunged by 160.98% to -$25.9 million in 2024, then slipped by 24.37% to -$32.2 million in 2025, then increased by 12.71% to -$28.1 million in 2026.
• Per Business Quant, the three latest JANX EBITDA figures stand at -$28.1 million (Q1 2026), -$32.2 million (Q4 2025), and -$23.5 million (Q3 2025).

Peer Comparison